IMUGENE LIMITED — Board/Management Information 2019

Nov 19, 2019

ASX Announcement

==> picture [116 x 42] intentionally omitted <==

Imugene appoints Professor Prasad S. Adusumilli MD FACS FCCP, of MSKCC to Oncolytic Virotherapy Scientific Advisory Board

---

Sydney, Australia, 20 November 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center at the Memorial Sloan Kettering Cancer Center in New York, to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB).

Dr. Adusimilli is a world-renowned thoracic surgeon with expertise in the diagnosis and treatment of cancers in the chest — lung cancer, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumors, and cancers metastatic to lung and pleura.

OVs are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

OVs have the potential to transform oncology by directly causing tumour cell death, and also by delivering a potent payload in a targeted fashion that activates the immune system.

Imugene’s M.D. & CEO, Ms Leslie Chong said, “It is a great honor for Imugene to have such a distinguished physician and scientist join our team. Dr. Adusumilli has devoted his career and his scientific discoveries for the benefit of cancer sufferers.”

For further information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

About Prof. Prasad S. Adusumilli, MD, FACS, FCCP

Deputy Chief and Attending, Thoracic Surgery

Vice Chair for Translational Research, Department of Surgery Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center Director, Mesothelioma Program

Memorial Sloan Kettering Cancer Center, NY.

Prof. Adusumilli’s research focuses on tumor immunology, chimeric antigen receptor (CAR) T-cell therapy, oncolytic viral therapy, and combination immunotherapy for cancers. Over the years, his team has developed clinically-relevant mouse models and modeled biological therapies in these models. This research has yielded mechanistic data that has been translated and is now in CAR T-cell and combination immunotherapy clinical trials for patients with lung cancer, pleural mesothelioma, and breast cancer. His ongoing research focuses on investigating immuno oncology agent’s efficacy in human ex vivo translational culture systems.

Prof. Adusumilli’s research has progressed to clinical trials and >210 publications including in Cancer Cell, Cancer Discov, FASEB, J Clin Invest, J Clin Oncol, J Natl Cancer Inst, Nat Med , and Sci Transl Med . In addition to serving on medical journal editorial boards, he is the Deputy Editor for Molecular Therapy Oncolytics . He serves as a member of national peer-review committees including NCI, DoD, PCORI, National health institutions of Austria, Belgium, Ireland, Italy, Poland, Netherlands, Switzerland, and the United Kingdom. He is an elected member of the Fleischner Society, American Society of Clinical Investigation, and American Surgical Association. He serves on international committees including the American Society of Cell and Gene Therapy, NCI thoracic cancers steering committee, International Association for the Study of Lung Cancer, and the American Association for Thoracic Surgery. In his laboratory, he mentors MDs, MD/PhDs, and PhDs in thoracic oncology research, including visiting scholars from international institutions.

2

IMUGENE LIMITED ACN 009 179 551

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

3

IMUGENE LIMITED ACN 009 179 551